Literature DB >> 35901837

CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy.

Satomi Ando1,2, Koichi Araki1,2.   

Abstract

Persistent antigenic stimulation results in loss of effector function or physical deletion of antigen-specific CD8 T cells. This T-cell state is called T-cell exhaustion and occurs during chronic infection and cancer. Antigen-specific CD8 T cells during T-cell exhaustion express the inhibitory receptor PD-1, the expression of which plays a major role in T-cell dysfunction. PD-1 blockade re-invigorates CD8 T-cell immunity and has been proven effective against many different types of human cancer. To further improve the efficacy of PD-1-targeted immunotherapy in cancer patients, a better understanding of T-cell exhaustion is required. Recent studies have revealed that antigen-specific CD8 T cells during T-cell exhaustion are heterogeneous and have also uncovered the detailed mechanisms for PD-1-targeted immunotherapy. Here, we review the CD8 T-cell subsets that arise during T-cell exhaustion, the lineage relationship among these individual subsets and the role of each subset in PD-1 blockade. Also, we discuss potential strategies to enhance the efficacy of PD-1-targeted immunotherapy.
© The Author(s) 2022. Published by Oxford University Press on behalf of The Japanese Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  T-cell exhaustion; T-cell heterogeneity; cancer; chronic infection; immune checkpoint inhibitors

Mesh:

Substances:

Year:  2022        PMID: 35901837      PMCID: PMC9533227          DOI: 10.1093/intimm/dxac038

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   5.071


  72 in total

1.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection.

Authors:  Hyun-Tak Jin; Ana C Anderson; Wendy G Tan; Erin E West; Sang-Jun Ha; Koichi Araki; Gordon J Freeman; Vijay K Kuchroo; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

2.  Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection.

Authors:  Ran He; Shiyue Hou; Cheng Liu; Anli Zhang; Qiang Bai; Miao Han; Yu Yang; Gang Wei; Ting Shen; Xinxin Yang; Lifan Xu; Xiangyu Chen; Yaxing Hao; Pengcheng Wang; Chuhong Zhu; Juanjuan Ou; Houjie Liang; Ting Ni; Xiaoyan Zhang; Xinyuan Zhou; Kai Deng; Yaokai Chen; Yadong Luo; Jianqing Xu; Hai Qi; Yuzhang Wu; Lilin Ye
Journal:  Nature       Date:  2016-08-02       Impact factor: 49.962

3.  Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.

Authors:  Henry Radziewicz; Chris C Ibegbu; Marina L Fernandez; Kimberly A Workowski; Kamil Obideen; Mohammad Wehbi; Holly L Hanson; James P Steinberg; David Masopust; E John Wherry; John D Altman; Barry T Rouse; Gordon J Freeman; Rafi Ahmed; Arash Grakoui
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

Review 4.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.

Authors:  Jérôme Galon; Daniela Bruni
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

5.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

6.  A vital role for interleukin-21 in the control of a chronic viral infection.

Authors:  John S Yi; Ming Du; Allan J Zajac
Journal:  Science       Date:  2009-05-14       Impact factor: 47.728

7.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.

Authors:  Se Jin Im; Masao Hashimoto; Michael Y Gerner; Junghwa Lee; Haydn T Kissick; Matheus C Burger; Qiang Shan; J Scott Hale; Judong Lee; Tahseen H Nasti; Arlene H Sharpe; Gordon J Freeman; Ronald N Germain; Helder I Nakaya; Hai-Hui Xue; Rafi Ahmed
Journal:  Nature       Date:  2016-08-02       Impact factor: 49.962

8.  Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

Authors:  Michael A Paley; Daniela C Kroy; Pamela M Odorizzi; Jonathan B Johnnidis; Douglas V Dolfi; Burton E Barnett; Elizabeth K Bikoff; Elizabeth J Robertson; Georg M Lauer; Steven L Reiner; E John Wherry
Journal:  Science       Date:  2012-11-30       Impact factor: 47.728

9.  Enhancing SIV-specific immunity in vivo by PD-1 blockade.

Authors:  Vijayakumar Velu; Kehmia Titanji; Baogong Zhu; Sajid Husain; Annette Pladevega; Lilin Lai; Thomas H Vanderford; Lakshmi Chennareddi; Guido Silvestri; Gordon J Freeman; Rafi Ahmed; Rama Rao Amara
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

10.  Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma.

Authors:  Giacomo Oliveira; Kari Stromhaug; Susan Klaeger; Tomasz Kula; Dennie T Frederick; Phuong M Le; Juliet Forman; Teddy Huang; Shuqiang Li; Wandi Zhang; Qikai Xu; Nicoletta Cieri; Karl R Clauser; Sachet A Shukla; Donna Neuberg; Sune Justesen; Gavin MacBeath; Steven A Carr; Edward F Fritsch; Nir Hacohen; Moshe Sade-Feldman; Kenneth J Livak; Genevieve M Boland; Patrick A Ott; Derin B Keskin; Catherine J Wu
Journal:  Nature       Date:  2021-07-21       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.